Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

Trial Details

NCT ID
NCT07680790
Phase
PHASE3
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Iza-bren
  • Osimertinib
  • Pemetrexed
  • Carboplatin
  • Cisplatin
Locations (sample)
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Fullerton, California, United States|33.87029,-117.92534
  • La Jolla, California, United States|32.84727,-117.2742
  • Boulder, Colorado, United States|40.01499,-105.27055
  • Fort Myers, Florida, United States|26.62168,-81.84059

Key Eligibility Criteria

  • Participants must have histologically or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), metastatic…
  • Participants must have documented EGFR-TKI-sensitizing mutation (exon 19 deletion or exon 21 L858R substitution)
  • Participants must have measurable extracranial disease per RECIST v1.1 as assessed by the investigator
  • Participants must have ECOG Performance Status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →